Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Biologically Targeted Vaccine for Chikungunya

Award Number: R41AI138964
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/20/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2021

Group Awards By:

View Award Description

Biologically Targeted Vaccine for Chikungunya - PROJECT SUMMARY/ABSTRACT Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humans. CHIKV caused an estimated 1.3 million new cases in India alone in 2006, and has the potential to spread globally because of the distribution and abundance of its mosquito vectors, Aedes aegypti and Aedes albopictus. During recent outbreaks more severe forms of CHIKV were observed, including encephalopathy and hemorrhagic fever, suggesting the emergence of more virulent strains. Closer to the US, in 2013-14 CHIKV has infected over 1.5 million people in South America and on multiple island nations of the Caribbean. Currently, no specific treatment or vaccine is available. Given its global burden, the increased travel into CHIKV-endemic areas, and the worldwide spread of its mosquito vector, there is a pressing need for the development of therapeutic agents and vaccines against CHIKV. Therefore, in order to reduce the impact of this virus and the devastating polyarthralgia that it causes, we must develop new therapies and vaccines to treat persistent CHIKV infections. The goal of this project is to evaluate and optimize immunogenicity and protection of novel dendritic cell-targeting Adenovirus CHIKV- vaccines in animal models of CHIKV infection. We will utilize our highly innovative DC-targeting strategy in conjunction with a simian Adenoviral backbone to circumvent prior immunity to human Adenoviruses. Development of this highly tractable vaccine platform is critical for its use for vaccination against other pathogens and cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	PRECISION VIROLOGICS INC	4340 DUNCAN AVE STE 203	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Allergy and Infectious Diseases Research	000	1	9/4/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $300,000 )
2019	2019	PRECISION VIROLOGICS INC	4041 FOREST PARK AVE	SAINT LOUIS	MO	63108	SAINT LOUIS CITY	USA	Allergy and Infectious Diseases Research	000	1	3/20/2019	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $300,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Biologically Targeted Vaccine for Chikungunya

Award Number: R41AI138964

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/20/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer